Wells Fargo's 'Core' Stocks: GOOGL, HD, KO, and More
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More
U.S. Tweaks 2025 Medicare Price Negotiation Process
Express News | Jefferies Financial raises novartis ag's target price from $123 to $124.
Express News | Novartis AG : Jefferies Raises Target Price to $124 From $123
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could Be Next
Teva Launches First U.S. Generic Against Novartis Antidiarrheal Sandostatin LAR
World Organization For Animal Health Says Germany Reports Outbreak Of Highly Pathogenic H5N1 Bird Flu On Farm In Eastern Part Of The Country
Novartis AG: A Balanced View of Opportunities and Challenges Ahead
European luxury goods concept stocks saw the largest weekly increase since 2012.
On Friday, September 27, the personal and household products index of the STOXX 600 index rose by 1.77%, marking a fifth consecutive trading day increase, with a total surge of 9.38% for the week. Data shows that among the component stocks, Henkel rose by 10.91% on Friday, Beiersdorf by 6.96%, Yunji Group by 6.34%, Ubisoft Entertainment by 5.94%, and Hugo Boss by 5.45% ranking fifth in performance, while LVMH Group rose by 3.67% ranking ninth in terms of increase. Meanwhile, L'Oreal dropped by 0.66%, marking the largest decrease among the three component stocks that fell. Among the "EU Eleven Heavenly Kings," Novo-Nordisk A/S dropped by 4.59%, while L'Oreal...
Perspective Draws Buy at Truist on Radiopharma Potential
MITEM PHARMA Acquires Worldwide Rights to DESFERAL (Deferoxamine) With the Backing of TECHLIFE CAPITAL and MACSF
Citi Sticks to Its Hold Rating for Novartis AG (NOVN)
Novartis AG Falls Tuesday, Underperforms Market
Generate:Biomedicines Announces Multi-Target Collaboration With Novartis to Discover and Develop Protein Therapeutics With Generative AI
UCB Gets Expanded FDA Approval for Psoriasis Drug Bimzelx
Prostate cancer RLT therapy has a promising future! Pluvicto, a subsidiary of Novartis AG (NVS.US), is expected to become a leader.
The radioactive ligand therapy (RLT) market is expected to experience significant growth by 2030, and Novartis AG's RLT product, Pluvicto, is expected to capture the largest share in the field of prostate cancer therapy.
Novartis' Pluvicto Expected to Dominate Prostate Cancer Radiopharmaceutical Market
Sword of Justice! The US FTC sues three major pharmaceutical "middlemen", vows to correct the distorted profit chain.
The USA's FTC announced on its official website that it has filed a lawsuit against three major "pharmacy benefit managers" and their affiliated organizations, accusing them of engaging in anti-competitive and unfair kickback practices. FTC also "clearly stated" in the declaration its deep concern about the roles played by eli lilly and co, novo-nordisk a/s, sanofi, and other insulin pharmaceutical companies, and the competition bureau may recommend prosecuting these pharmaceutical companies in future enforcement actions.
How Critical Demand for Metastatic Breast Cancer Therapies Is Producing a Multi-Billion Dollar Opportunity for Biotechs